Aims and objectives
The aim of the litterature studywas tocompare research which use fused PET/CT for planning of radiotherapy and permit an increased radiation dose to the malignant tissue. Common to the included projects was that they focused on the metabolic charging of FDG in the scan to define the tumor volume.
By defining the active volume of the tumor,
studies have shown that it will be possible to change the threatment dose in different ways.
Either byreducing the PTV (planned tumor volume) to only cover...
Methods and materials
The litterature study was done on the basis of 8 selected scientific studies,
which used different methods to examine the outcome of the use of PET/CT for radiotheraphy planning. The studies was selected using a systematic block search in the3 large international databases Pubmed,
AcademicSearch and Medline.
A number of inclusion and exclusion criterias were set up to make sure the studies was relevant for this study. The included studies had an average of 37 [10:87] recruited patients.
When defining the tumor volume using FDG PET/CT,
it is possible to escalate the mean dose from 62,8 Gy [62,5-66] to 88 Gy [74,9-134,9] without exceeding the dose restriction for the OAR.
The results also showed that even though OAR restrictions was met in the planning of the radiotherapy ,
a higher dose equals a higher risk of severe side effects from the treatment.
This despite all studies OAR restriktions was held underneath the restritions for all tissue set by QUANTEC.
The use of fused PET/CT for radiotheraphy planning will affect the given dose to both target and OAR.
Common to the included studies is,
that PET/CT plays an essential role in the outcome for the patients treatment effect and side effects.
the studies show prominent advantages and disadvantages,
meaning that the definition of the best result depends on the focus If the goal is to get the biggest dose escalation,
study two has the best results.
If the goal is the smallest PTV,
Drøgemüller Lund M,
Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized,
multi-centre phase-III study.
Radiother Oncol [Internet].
2017 [cited 2018 May 16]; 124(2):311–7 2.
Stoep J van der,
PET-based dose painting in non-small cell lung cancer: Comparing uniform dose escalation with...